Appili Therapeutics Inc. (APLI.TO)
CAD 0.04
(-12.5%)
CAD 0.04
(-12.5%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.03 CAD | 61.62% |
| 2022 | -0.08 CAD | 78.61% |
| 2021 | -0.38 CAD | -58.33% |
| 2020 | -0.24 CAD | -50.0% |
| 2019 | -0.16 CAD | -14.29% |
| 2018 | -0.14 CAD | -16.67% |
| 2017 | -0.12 CAD | -107.25% |
| 2016 | -0.06 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.01 CAD | -43.96% |
| 2023 Q4 | -0.01 CAD | -600.0% |
| 2023 FY | - CAD | 61.62% |
| 2023 Q3 | -0.00 CAD | 83.95% |
| 2023 Q2 | -0.01 CAD | 36.72% |
| 2023 Q1 | -0.01 CAD | 41.55% |
| 2022 Q1 | -0.03 CAD | 45.51% |
| 2022 Q4 | -0.02 CAD | -1.39% |
| 2022 FY | - CAD | 78.61% |
| 2022 Q3 | -0.02 CAD | -60.0% |
| 2022 Q2 | -0.01 CAD | 47.06% |
| 2021 Q3 | -0.05 CAD | 74.33% |
| 2021 FY | - CAD | -58.33% |
| 2021 Q1 | -0.12 CAD | -50.75% |
| 2021 Q2 | -0.18 CAD | -50.0% |
| 2021 Q4 | -0.05 CAD | -1.3% |
| 2020 FY | - CAD | -50.0% |
| 2020 Q1 | -0.05 CAD | -58.1% |
| 2020 Q4 | -0.08 CAD | -16.03% |
| 2020 Q3 | -0.07 CAD | -70.65% |
| 2020 Q2 | -0.04 CAD | 22.24% |
| 2019 Q3 | -0.04 CAD | -2.63% |
| 2019 Q2 | -0.03 CAD | 42.42% |
| 2019 Q1 | -0.06 CAD | -52.31% |
| 2019 FY | - CAD | -14.29% |
| 2019 Q4 | -0.03 CAD | 6.84% |
| 2018 FY | - CAD | -16.67% |
| 2018 Q4 | -0.04 CAD | -8.33% |
| 2018 Q1 | -0.01 CAD | 69.94% |
| 2018 Q2 | -0.04 CAD | -175.69% |
| 2018 Q3 | -0.04 CAD | 9.32% |
| 2017 FY | - CAD | -107.25% |
| 2017 Q4 | -0.05 CAD | -21.88% |
| 2017 Q3 | -0.04 CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. | -1.58 CAD | 98.025% |
| Helix BioPharma Corp. | -0.21 CAD | 85.143% |
| Microbix Biosystems Inc. | -0.00 CAD | -10300.0% |
| Medicenna Therapeutics Corp. | -0.37 CAD | 91.568% |
| Satellos Bioscience Inc. | -0.18 CAD | 82.667% |
| Oncolytics Biotech Inc. | -0.41 CAD | 92.39% |
| Sernova Corp. | -0.13 CAD | 76.0% |